IMO Health provides healthcare AI solutions designed to transform healthcare data into trusted clinical context. Through this pilot, San Diego-based Modular Medical aims to develop a deployable terminology-powered phenotypic algorithm designed to identify diabetes patients who may benefit from insulin pump therapy directly within the electronic health record (EHR).
Modular Medical said the pilot seeks to help clinicians successfully identify multiple‑daily‑injection (MDI) patients who exhibit clinical characteristics associated with insulin pump hesitancy or prior pump failure. It could enable more timely, targeted conversations about modern pump therapy options like the company’s Pivot system.
Pivot, designed to make insulin pump therapy simpler to learn and easier to live with, features a removable, two-part design and a 3 mL reservoir, intuitive interface and flexible, wearable form factor. The system aims to support everyday activities, like showering and sports, with no battery charging required, all while maintaining clinical accuracy and connectivity.
Pivot won FDA 510(k) clearance in April. Modular Medical labels it the second fully electronic, tubeless insulin pump available in the U.S. It launched the system last month.
The company plans to pilot the initiative with a large-scale diabetes center ahead of the full rollout of Pivot. It wants to establish a scalable framework for multi-site deployment to ensure consistent performance across diverse environments.
More about the partnership
Modular Medical and IMO Health say they took input from expert clinicians to define the clinical characteristics commonly observed in patients who either avoided pump therapy or discontinued traditional pumps.
Those include phenotypic patterns associated with suboptimal MDI outcomes and pump-hesitancy traits. Such traits include concerns over device complexity, alarm burden or lifestyle disruption. Additionally, they report pump-failure indicators like infusion set challenges, workflow friction or interface management difficulties.
Using these insights, they formed the foundation of a terminology-powered phenotypic model, made actionable within the EHR.
IMO Health intends to translate the defined characteristics into validated terminology value sets. These emulate clinical reasoning and identify patients with an elevated likelihood of benefiting from pump therapy.
Once deployed, the companies expect this to help identify MDI patients failing to meet glycemic targets or requiring emergency room visits, surface pump-eligible candidates during routine visits, reduce clinical burden by automating complex chart review and support equitable access to advanced diabetes technology.
Commentary from Modular Medical and IMO Health officials
Jeb Besser, Modular Medical CEO, said:
“Commercial success isn’t only about building a better insulin pump, it’s about helping clinicians identify the patients who will benefit from it. This collaboration with IMO Health should allow us to find those patients more effectively and bring modern pump therapy to individuals who may have been underserved by existing technologies, while minimizing clinician effort in identification. We believe this capability can become an important component of our commercial strategy as Pivot launches and scales.”
Matt McKinley, EVP and GM of Life Sciences at IMO Health, said:
“Clinicians often know which patients could benefit from pump therapy but identifying them within the EHR can be time consuming and inconsistent. By combining our terminology expertise with Modular Medical’s clinician guided phenotypes, we expect to create a practical, scalable tool that reduces burden on clinicians and helps ensure patients who stand to benefit from pump therapy are not overlooked.”
